DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial

MLA

Christopher L. Brown, et al. “DREAM3R: Durvalumab with Chemotherapy as First-Line Treatment in Advanced Pleural Mesothelioma—A Phase 3 Randomized Trial.” Journal of Clinical Oncology, vol. 40, June 2022, p. TPS8599. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.tps8599.

APA

Christopher L. Brown, Marjorie G. Zauderer, Anne S. Tsao, Anna K. Nowak, Kenneth J. O’Byrne, Peey-Sei Kok, Suresh S. Ramalingam, Alistair M. Cook, Valsamo Anagnostou, Sonia Yip, Hedy L. Kindler, Nick Pavlakis, Z. Sun, Julie R. Brahmer, Willem Joost Lesterhuis, Martin R. Stockler, Patrick M. Forde, & Brett G.M. Hughes. (2022). DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial. Journal of Clinical Oncology, 40, TPS8599. https://doi.org/10.1200/jco.2022.40.16_suppl.tps8599

Chicago

Christopher L. Brown, Marjorie G. Zauderer, Anne S. Tsao, Anna K. Nowak, Kenneth J. O’Byrne, Peey-Sei Kok, Suresh S. Ramalingam, et al. 2022. “DREAM3R: Durvalumab with Chemotherapy as First-Line Treatment in Advanced Pleural Mesothelioma—A Phase 3 Randomized Trial.” Journal of Clinical Oncology 40 (June): TPS8599. doi:10.1200/jco.2022.40.16_suppl.tps8599.